Lung cancer treatment is evolving, with combination therapies providing a more personalized approach to care. Lauren Byers, M.D., and Ferdinandos Skoulidis, M.D., Ph.D., discuss how targeted therapy and immunotherapy are being used together to improve outcomes, the importance of biomarkers in guiding treatment decisions and new advances in KRAS research. They also explore the growing role of personalized immunotherapy and antibody-drug conjugates, including how these approaches may reduce reliance on chemotherapy, and what this means for patients facing lung cancer today.